Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 782 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients... November 2, 2023 A Safer, Better Treatment Option for Some Younger Women with Breast... January 11, 2023 Same Breast Cancer, Same Place, Same Treatment. This Mother and Daughter... May 7, 2021 Changes to chromosomes impact how children’s brain tumours respond to treatment November 4, 2022 Load more HOT NEWS Groom Uses Wedding To Ask Stepdaughters If He Can Adopt Them 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer Easy Meals at Home
